MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584283 | Name: Todralazine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Todralazine is an antihypertensive agent with both central and peripheral action; it has some central nervous system depressant effects.

Chemical Structure

Todralazine
CAS#14679-73-3

Theoretical Analysis

MedKoo Cat#: 584283

Name: Todralazine

CAS#: 14679-73-3

Chemical Formula: C11H12N4O2

Exact Mass: 232.0960

Molecular Weight: 232.24

Elemental Analysis: C, 56.89; H, 5.21; N, 24.12; O, 13.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Todralazine
IUPAC/Chemical Name
Carbazic acid, 3-(1-phthalazinyl)-, ethyl ester
InChi Key
WGZDBVOTUVNQFP-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H12N4O2/c1-2-17-11(16)15-14-10-9-6-4-3-5-8(9)7-12-13-10/h3-7H,2H2,1H3,(H,13,14)(H,15,16)
SMILES Code
O=C(OCC)NNC1=NN=CC2=C1C=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 232.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dimri M, Joshi J, Chakrabarti R, Sehgal N, Sureshbabu A, Kumar IP. Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion. Zebrafish. 2015 Feb;12(1):33-47. doi: 10.1089/zeb.2014.0992. Epub 2014 Dec 17. PubMed PMID: 25517940; PubMed Central PMCID: PMC4298150. 2: Gasiorowski K, Brokos B. Evaluation of antimutagenic effect of todralazine in cultured lymphocytes. Mutagenesis. 2000 Mar;15(2):137-41. PubMed PMID: 10719039. 3: Gasiorowski K, Szyba K, Wozniak D, Gulanowski B. Inhibition of potassium dichromate mutagenicity by todralazine. Mutagenesis. 1997 Nov;12(6):411-5. PubMed PMID: 9412993. 4: Elsharkawy AM. Todralazine hepatotoxicity: a sting in the histone tail. J Hepatol. 2007 Feb;46(2):189-92. Epub 2006 Dec 1. PubMed PMID: 17161489. 5: Jastrzebski Z, Czyzewska-Szafran H, Goźlińska B, Wutkiewicz M, Jedrych A, Fijałek Z, Biniecki K, Aranjo P, Ciszewski L, Mazurek AP. Acute systemic toxicity and antihypertensive activity of a novel todralazine analog in rats. Acta Pol Pharm. 1993;50(4-5):327-30. PubMed PMID: 8036918. 6: Gasiorowski K, Szyba K, Sawicka J, Gulanowski B. Mutagenicity of B(a)P in the presence of some hydralazine derivatives. Pol J Occup Med Environ Health. 1993;6(4):383-9. PubMed PMID: 8019200. 7: Gomez de Balugera Z, Arantzazu Goicolea M, Barrio RJ. Joint determination of todralazine and acetazolamide in human serum by differential pulse polarography. J Pharm Biomed Anal. 1994 Jul;12(7):883-7. PubMed PMID: 7981316. 8: Gasiorowski K, Szyba K, Sawicka J, Gulanowski B. Evaluation of the mechanisms of todralazine effect on mutagenicity of benzo(a)pyrene. Int J Occup Med Environ Health. 1995;8(3):267-73. PubMed PMID: 8581334. 9: Olczyk K, Kucharz EJ, Drózdz M. Influence of long-term treatment with hydrazinophthalazines on the activity of lysosomal exoglycosidases in rat tissues. Acta Med Hung. 1988;45(2):161-9. PubMed PMID: 3266791. 10: Reiterer W, Czitober H. [The influence of guanazodine and todralazine on blood pressure regulation during dynamic and static exercise in essential hypertension (author's transl)]. Arzneimittelforschung. 1977;27(11):2163-7. German. PubMed PMID: 580022. 11: Gasiorowski K, Gulanowski B, Szyba K, Urban J. Study of the mechanism of todralazine antimutagenic activity: the effect upon mutagenicity of daunorubicine. Int J Occup Med Environ Health. 1994;7(4):371-8. PubMed PMID: 7719664. 12: Gasiorowski K, Szyba K, Urban J. Todralazine influence upon the mutagenicity of some direct- and indirect-acting mutagens. Mutat Res. 1994 Jul;324(3):133-7. PubMed PMID: 7517512. 13: Murata K, Hamada M, Sugimoto K, Nakano T. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. J Hepatol. 2007 Feb;46(2):322-9. Epub 2006 Nov 3. PubMed PMID: 17156885. 14: Gasiorowski K, Brokos B. DNA repair of hydrogen peroxide-induced damage in human lymphocytes in the presence of four antimutagens. A study with alkaline single cell gel electrophoresis (comet assay). Cell Mol Biol Lett. 2001;6(4):897-911. PubMed PMID: 11753436. 15: Kedrowa S, Markiewicz M, Kolber-Postepska B, Kudlicki J. [Hypotensive action of binazine in the light of our studies]. Wiad Lek. 1980 Mar 15;33(6):421-6. Polish. PubMed PMID: 7385877. 16: Gasiorowski K, Brokos B, Kulma A, Ogorzałek A, Skórkowska K. Impact of four antimutagens on apoptosis in genotoxically damaged lymphocytes in vitro. Cell Mol Biol Lett. 2001;6(3):649-75. PubMed PMID: 11598640. 17: Cybulska I. [Phthalazine derivatives in the treatment of arterial hypertension]. Kardiol Pol. 1981;24(10):709-15. Polish. PubMed PMID: 7329009. 18: Weglarz L, Drózdz M, Wardas M. Influence of hydrazinophthalazines on the activity of collagenase in murine fibroblast culture. Biomed Biochim Acta. 1990;49(4):289-91. PubMed PMID: 2169725. 19: Falase AO, Salako LA. Clinical experience with a new vasodilator, binazine, in Nigerian hypertensives. Niger Med J. 1979 May-Jun;9(5-6):577-84. PubMed PMID: 525046. 20: Dohi Y, Kojima M, Sato K. Benidipine improves endothelial function in renal resistance arteries of hypertensive rats. Hypertension. 1996 Jul;28(1):58-63. PubMed PMID: 8675265.